4.5 Article

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Journal

EUROPEAN JOURNAL OF NUTRITION
Volume 61, Issue 1, Pages 477-487

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00394-021-02666-1

Keywords

Glioblastoma; Radiation; Ketogenic diet; Fasting; Glucose; Leptin

Funding

  1. Projekt DEAL
  2. Senckenberg Foundation
  3. investigatorinitiated trial (IIT) program of the University Cancer Center Frankfurt (UCT).

Ask authors/readers for more resources

The prospective ERGO2 trial investigated the effects of calorie-restricted ketogenic diet and intermittent fasting on re-irradiation for recurrent brain tumors, showing that the ketogenic diet did not improve progression-free survival. Unexpectedly, the control group had lower calorie intake than expected, while the ketogenic diet group met the preset goals for calorie and carbohydrate restriction.
Purpose The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21-23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available